ESTRO37_ProgrammeBook

10:40 > Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer W.U. Shipley (USA), P. Zhang, P. Saylor, C. Lee, C.L. Wu, W. Parker, T. Lautenschlaeger, A. Zietman, J. Efstathiou, A. Jani, O. Kucuk, L. Souhami, J. Rodgers, H. Sandler, J. Coen 10:50 > Clinical outcomes of the first RCT of adaptive radiotherapy in bladder cancer (HYBRID CRUK/12/055) R. Huddart (United Kingdom), A. Henry, J. Staffurth, I. Syndikus, A. Mitra, R. Venkitraman, H. McNair, V. Khoo, E. Lewis, C. Vassallo-Bonner, A. Baker, G. Horan, E. Parsons, S. Moinuddin, V. Hansen, A. Birtle, S. Hafeez, A. Goubar, E. Hall 11:00 > Four- or 5-weeks of radiotherapy for prostate cancer: interim results of a randomized phase 3 trial 11:10 > Health-related Quality of Life from the prostate hypofractionation (HYPRO) trial F. Pos, R.C. Wortel, W.D. Heemsbergen (The Netherlands), E. Oomen-de Hoop, L. Incrocci 11:20 > Big-RT: Big Data analysis to identify predictors of radiotherapy toxicity for personalised treatment V. Fonteyne (Belgium), M. Swimberghe, E. Rammant, G. De Meerleer, B. Vanderstraeten, F. Vanpachtenbeke, N. Lumen, K. Decaestecker, P. Ost

SATURDAY 21 APRIL 2018

OC-0057

 OC-0058

OC-0059

 OC-0060

N. Somaiah (United Kingdom), S. Poelsterl, C. Rodriguez-Gonzalvez, A. Wilkins, S. Gulliford, J. Campbell, S. Yu, V. Garcia-Perez, C. Griffin, J. Bliss, J. Yarnold, U. Oelfke, D. Dearnaley, E. Hall, B. Al-Lazikani

 OC-0061

11:30 > Phase II trial of SBRT and Hormone therapy for Oligometastases in Prostate Cancer (SBRT-SG 05)

A. Conde Moreno (Spain), F. Lopez Campos, A. Hervás Morón, C. Vallejo Ocaña, J. Valero Albarrán, A. Mendez Villamón, M. Puertas Valiño, A. Gómez-Iturriaga, P. Samper Ots, A. Sola Galarza, M. Rico Oses, C. Ibañez Villaoslada, L.A. Pérez-Romasanta, J. Pastor Peidró, J. López-Torrecilla, F. Ferrer González, N. Ortiz Rodil, F. García Piñon, A. Rodríguez Pérez, C. Ferrer Albiach

OC-0062

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

78